Google Ad

Dr Reddy’s launches Redyx (Remdesivir) in India for COVID-19 therapy – Home Health Choices

Hyderabad: Dr Reddy’s Laboratories on Wednesday introduced the launch of Remdesivir beneath the model title Redyx for Indian markets.

The launch is a part of a licensing settlement with Gilead Sciences Inc that grants Dr Reddy’s the precise to register, manufacture and promote Remdesivir, a possible therapy for COVID-19, in 127 international locations together with India.

Remdesivir is permitted by Drug Controller General of India (DCGI) for restricted emergency use in India for the therapy of Covid-19 sufferers hospitalised with extreme signs.

Dr Reddy’s Redyx is out there within the energy of 100 mg vial.

“We will continue our efforts to develop products that address significant unmet needs of patients,” stated M V Ramana, Chief Executive Officer for branded markets (India and rising markets) at Dr Reddy’s.

“The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India,” he stated in a press release.

Last month, Dr Reddy’s introduced the launch of Avigan (Favipiravir) 200 mg tablets in India for therapy of sufferers with gentle to average COVID-19 disease.

The launch was part of a world licensing settlement with Fujifilm Toyama Chemical that grants Dr Reddy’s unique rights to fabricate, promote and distribute Avigan tablets in India.

Latest Updates

Related Post